糖尿病足患者血浆尾加压素Ⅱ的变化及临床意义  

Changes and the clinical significance of plasma urotensin Ⅱ in patients with diabetic foot

作　　者：柴国禄[1] 张阳阳[1] 杨玉红[1] 谭丽艳[1] 庞建伟[1] 

机构地区：[1]佳木斯大学附属第一医院内分泌科,黑龙江佳木斯154003

出　　处：《中国现代医学杂志》2008年第23期3494-3496,3499,共4页China Journal of Modern Medicine

摘　　要：目的探讨糖尿病足患者血浆尾加压素Ⅱ(urotensinⅡ,UⅡ)、肾上腺髓质素(adrenomedullin,ADM)水平的变化及在糖尿病足发病中的可能作用。方法测定30例无糖尿病足糖尿病患者、62例糖尿病足患者和30例正常对照组血浆UⅡ、ADM水平,分析血浆UⅡ、ADM水平变化与糖尿病足发病的关系,观察木倍丙酯治疗对糖尿病足患者血浆UⅡ、ADM水平的影响。结果糖尿病足患者血浆UⅡ、ADM水平较无糖尿病足糖尿病患者明显升高(均P<0.01),糖尿病足患者血浆UⅡ与ADM水平呈明显正相关(r=0.576,P<0.01)。应用木倍丙酯治疗后糖尿病足患者血浆UⅡ、ADM水平明显降低(均P<0.01)。结论血浆UⅡ、ADM水平升高在糖尿病足发病中发挥重要作用,木倍丙酯治疗可使糖尿病足患者血浆UⅡ、ADM水平降低,促进病变恢复。ObjectiveTo study the change of plasma urotensin Ⅱ(UⅡ) and adrenomedullin(ADM) and possible role in the development of diabetic foot. MethodsThe levels of plasma UⅡ and ADM were measured in 30 diabetic patients without diabetic foot,62 patients with diabetic foot and 30 normal individuals. The relationship between the changes of plasma UⅡ and ADM levels and the development of diabetic foot was analysed. To explore the influence of Prpylgallate(Beibingzhi) on plasma levehs of UⅡ and ADM in patients with diab...

关 键 词：糖尿病足 尾加压素Ⅱ 肾上腺髓质素 

分 类 号：R587.2[医药卫生—内分泌]